Woodline Partners LP Invests $8.69 Million in Capricor Therapeutics Inc (NASDAQ:CAPR)

Woodline Partners LP acquired a new position in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 629,934 shares of the biotechnology company's stock, valued at approximately $8,693,000. Woodline Partners LP owned 1.39% of Capricor Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CAPR. Farallon Capital Management LLC acquired a new position in shares of Capricor Therapeutics in the fourth quarter worth approximately $31,056,000. Vanguard Group Inc. increased its holdings in shares of Capricor Therapeutics by 44.4% during the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company's stock valued at $31,420,000 after acquiring an additional 700,243 shares in the last quarter. Altium Capital Management LLC increased its holdings in shares of Capricor Therapeutics by 150.5% during the fourth quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company's stock valued at $9,853,000 after acquiring an additional 429,000 shares in the last quarter. Black Diamond Financial LLC purchased a new position in shares of Capricor Therapeutics during the fourth quarter valued at approximately $3,833,000. Finally, Geode Capital Management LLC boosted its position in shares of Capricor Therapeutics by 37.8% during the fourth quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company's stock valued at $12,139,000 after buying an additional 241,279 shares during the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently commented on CAPR. HC Wainwright reaffirmed a "buy" rating and set a $77.00 price target on shares of Capricor Therapeutics in a research report on Monday, March 17th. Roth Capital initiated coverage on Capricor Therapeutics in a research note on Tuesday, May 20th. They issued a "buy" rating and a $31.00 target price on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $30.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. Finally, Wall Street Zen cut Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $35.50.

Capricor Therapeutics Price Performance

CAPR stock traded down $0.07 on Wednesday, reaching $10.41. 248,022 shares of the company traded hands, compared to its average volume of 1,726,120. Capricor Therapeutics Inc has a one year low of $3.52 and a one year high of $23.40. The company has a market cap of $475.50 million, a P/E ratio of -9.82 and a beta of 0.85. The firm has a fifty day simple moving average of $10.39 and a 200-day simple moving average of $13.31.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). The business had revenue of $2.73 million during the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. During the same period in the previous year, the business posted ($0.31) EPS. On average, sell-side analysts forecast that Capricor Therapeutics Inc will post -1.21 EPS for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.